News tagged with cetuximab

Related topics: cancer , colon cancer , colorectal cancer , monoclonal antibodies

Unexpected results in cancer drug trial

Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.

Apr 08, 2014
popularity 3 / 5 (1) | comments 0

New type of bowel cancer discovered

(Medical Xpress)—A unique sub-type of bowel cancer has been discovered which has a worse outcome than other types of colon cancer and is resistant to certain targeted treatments, according to research published ...

Apr 15, 2013
popularity 5 / 5 (3) | comments 0 | with audio podcast

Smoking worsens outcomes with advanced colon cancer

(HealthDay)—Smoking is tied to significantly shorter disease-free survival (DFS) and time to recurrence (TTR) in patients undergoing treatment for stage III colon cancer, according to a study published ...

Apr 06, 2013
popularity 5 / 5 (1) | comments 2

Scientists find a new way to boost common cancer drugs

Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center, published in the January issue ...

Jan 14, 2013
popularity 5 / 5 (2) | comments 0 | with audio podcast

Cetuximab, paclitaxel combo active in urothelial cancer

(HealthDay)—The monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according ...

Aug 29, 2012
popularity not rated yet | comments 0

New test helps evaluate cancer drug's merit

(HealthDay) -- A new genetic test to help doctors determine if the drug Erbitux would be an effective treatment for certain colorectal cancer patients has been approved by the U.S. Food and Drug Administration.

Jul 09, 2012
popularity not rated yet | comments 0

Dose-escalated cetuximab tolerated in colorectal cancer

(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience ...

Jul 05, 2012
popularity not rated yet | comments 0

Cetuximab

Cetuximab (IMC-C225—marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer.

This text uses material from Wikipedia licensed under CC BY-SA